X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215266
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215266
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-11-2022-1652250109.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-30-2022-1648618596.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-26-2022-1643358623.pdf
https://www.prnewswire.com/news-releases/ortho-dermatologics-to-present-new-data-at-the-2021-fall-clinical-dermatology-conference-301402874.html
https://www.prnewswire.com/news-releases/fda-approves-lexette-r-for-adolescent-plaque-psoriasis-301381150.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214285
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211464
https://www.pharmacompass.com/pdf/news/health-canada-issues-recall-of-bausch-health-canada-s-ultravate-1587445813.pdf
https://en.prnasia.com/releases/global/fda-approves-trade-name-lexette-tm-halobetasol-propionate-foam-0-05--244584.shtml
https://www.cnbc.com/2019/04/25/shares-of-bausch-health-formerly-known-as-valeant-rise-3percent-on-fda-approval-for-psoriasis-treatment.html
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-bryhali-209355-halobetasol-propionate-for-lotion-001-1560927764.pdf
https://www.biospectrumasia.com/news/25/12805/mayne-pharma-launches-anti-plaque-psoriasis-agent-in-us.html
https://en.prnasia.com/releases/global/mayne-pharma-launches-lexette-tm-halobetasol-propionate-foam-0-05-in-the-united-states-237041.shtml
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211464
https://www.fiercepharma.com/marketing/cosmo-to-give-bausch-health-sales-a-run-latest-fda-nod-for-xifaxan-rival
https://www.fiercepharma.com/pharma/bausch-health-quickly-revives-fda-quest-for-significant-7-hopeful-duobrii
https://www.in-pharmatechnologist.com/Article/2018/06/19/US-FDA-rejects-Valeant-s-Duobrii-for-plaque-psoriasis
https://www.fiercepharma.com/pharma/valeant-dealt-a-major-setback-as-psoriasis-dual-drug-lotion-duobrii-fails-to-impress-fda
https://endpts.com/valeant-nosedives-on-crl-for-plaque-psoriasis-raising-concerns-over-touted-1b-pipeline/
https://www.prnewswire.com/news-releases/perrigo-confirms-first-to-file-patent-challenge-for-generic-version-of-ultravate-lotion-0-05-300647625.html
https://www.pharmacompass.com/pdf/news/ultravate-halobetasol-propionate-sun-pharmaceutical-v-perrigo-company-1526283545.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-ultavate-halobetasol-propionate-new-lotion-1522389930.pdf
https://globenewswire.com/news-release/2018/03/21/1443595/0/en/Teligent-Inc-Announces-FDA-Approval-of-Halobetasol-Propionate-Ointment-0-05.html
http://www.dddmag.com/news/2016/12/valeant-pharmaceuticals-posts-phase-3-results-psoriasis-treatment
https://www.pharmacompass.com/pdf/news/ferndale-labs-ultravate-approved-in-us-for-dermatological-use-1447317035.pdf
Market Place
Share 
